(ARQT) Arcutis Biotherapeutics - Ratings and Ratios
Topical Cream, Seborrheic Dermatitis, Plaque Psoriasis, Atopic Dermatitis
ARQT EPS (Earnings per Share)
ARQT Revenue
Description: ARQT Arcutis Biotherapeutics
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) is a biotechnology company listed on the NASDAQ stock exchange, operating in the biotechnology sub-industry. The companys stock is categorized as a common stock and is of US origin.
To evaluate the companys stock performance, we can look at key technical indicators. The stocks last price was $14.19, with moving averages indicating a relatively stable trend (SMA20: $14.82, SMA50: $14.29). The Average True Range (ATR) of 0.71 represents a 5.04% volatility, suggesting moderate price fluctuations. With a beta of 1.845, the stock is considered relatively volatile compared to the overall market.
From a fundamental analysis perspective, Arcutis Biotherapeutics has a market capitalization of $1.771 billion. The absence of a Price-to-Earnings (P/E) ratio, both current and forward, indicates that the company is likely not profitable. The Return on Equity (RoE) stands at -62.62%, further suggesting significant losses. To turn profitable, the company needs to effectively manage its research and development expenses, commercialization costs, and other operational expenditures.
Key economic drivers for Arcutis Biotherapeutics include the successful development and commercialization of its drug pipeline, particularly in the dermatology and inflammatory disease spaces. The companys ability to secure partnerships, obtain regulatory approvals, and navigate the competitive landscape will be crucial in driving growth. Key Performance Indicators (KPIs) to watch include the progress of its lead candidates through clinical trials, cash burn rate, and the companys ability to secure additional funding to support its operations.
To assess the stocks potential, investors should monitor the companys cash position, upcoming clinical trial results, and any strategic partnerships or collaborations that could impact its financials and growth prospects. A thorough analysis of these factors will help determine whether the current stock price accurately reflects the companys prospects and potential for future growth.
ARQT Stock Overview
| Market Cap in USD | 1,837m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2020-01-31 |
ARQT Stock Ratings
| Growth Rating | 15.1% |
| Fundamental | 30.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 40.0% |
| Analyst Rating | 4.57 of 5 |
ARQT Dividends
Currently no dividends paidARQT Growth Ratios
| Growth Correlation 3m | 83.6% |
| Growth Correlation 12m | 75.3% |
| Growth Correlation 5y | -74.2% |
| CAGR 5y | -1.83% |
| CAGR/Max DD 3y | -0.02 |
| CAGR/Mean DD 3y | -0.04 |
| Sharpe Ratio 12m | 0.34 |
| Alpha | 0.00 |
| Beta | 0.983 |
| Volatility | 57.40% |
| Current Volume | 1274.8k |
| Average Volume 20d | 1412.4k |
| Stop Loss | 16.9 (-4.5%) |
| Signal | -0.46 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-93.3m TTM) > 0 and > 6% of Revenue (6% = 15.8m TTM) |
| FCFTA -0.32 (>2.0%) and ΔFCFTA 23.78pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 86.86% (prev 290.2%; Δ -203.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.19 (>3.0%) and CFO -65.5m > Net Income -93.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.20 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (127.0m) change vs 12m ago 2.85% (target <= -2.0% for YES) |
| Gross Margin 89.10% (prev 92.32%; Δ -3.22pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 66.10% (prev 29.69%; Δ 36.41pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.07 (EBITDA TTM -68.5m / Interest Expense TTM 18.2m) >= 6 (WARN >= 3) |
Altman Z'' -13.47
| (A) 0.65 = (Total Current Assets 332.8m - Total Current Liabilities 103.9m) / Total Assets 352.4m |
| (B) -3.30 = Retained Earnings (Balance) -1.16b / Total Assets 352.4m |
| warn (B) unusual magnitude: -3.30 — check mapping/units |
| (C) -0.19 = EBIT TTM -74.1m / Avg Total Assets 398.6m |
| (D) -5.45 = Book Value of Equity -1.16b / Total Liabilities 213.5m |
| Total Rating: -13.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 29.98
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -6.40% = -3.20 |
| 3. FCF Margin -42.62% = -7.50 |
| 4. Debt/Equity 0.78 = 2.21 |
| 5. Debt/Ebitda -1.58 = -2.50 |
| 6. ROIC - WACC -35.62% = -12.50 |
| 7. RoE -62.62% = -2.50 |
| 8. Rev. Trend 91.45% = 4.57 |
| 9. Rev. CAGR 456.9% = 2.50 |
| 10. EPS Trend 96.05% = 2.40 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of ARQT shares?
Over the past week, the price has changed by +9.13%, over one month by +24.67%, over three months by +28.84% and over the past year by +68.16%.
Is Arcutis Biotherapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARQT is around 18.74 USD . This means that ARQT is currently overvalued and has a potential downside of 5.94%.
Is ARQT a buy, sell or hold?
- Strong Buy: 4
- Buy: 3
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ARQT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.9 | 23.6% |
| Analysts Target Price | 21.9 | 23.6% |
| ValueRay Target Price | 21 | 18.9% |
Last update: 2025-09-04 04:31
ARQT Fundamental Data Overview
CCE Cash And Equivalents = 191.1m USD (Cash And Short Term Investments, last quarter)
P/S = 6.9723
P/B = 13.3905
Beta = 1.845
Revenue TTM = 263.5m USD
EBIT TTM = -74.1m USD
EBITDA TTM = -68.5m USD
Long Term Debt = 107.0m USD (from longTermDebt, last quarter)
Short Term Debt = 1.00m USD (from shortTermDebt, last quarter)
Debt = 108.0m USD (Calculated: Short Term 1.00m + Long Term 107.0m)
Net Debt = 37.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.75b USD (1.84b + Debt 108.0m - CCE 191.1m)
Interest Coverage Ratio = -4.07 (Ebit TTM -74.1m / Interest Expense TTM 18.2m)
FCF Yield = -6.40% (FCF TTM -112.3m / Enterprise Value 1.75b)
FCF Margin = -42.62% (FCF TTM -112.3m / Revenue TTM 263.5m)
Net Margin = -35.40% (Net Income TTM -93.3m / Revenue TTM 263.5m)
Gross Margin = 89.10% ((Revenue TTM 263.5m - Cost of Revenue TTM 28.7m) / Revenue TTM)
Tobins Q-Ratio = -1.51 (set to none) (Enterprise Value 1.75b / Book Value Of Equity -1.16b)
Interest Expense / Debt = 2.80% (Interest Expense 3.03m / Debt 108.0m)
Taxrate = 21.0% (US default)
NOPAT = -74.1m (EBIT -74.1m, no tax applied on loss)
Current Ratio = 3.20 (Total Current Assets 332.8m / Total Current Liabilities 103.9m)
Debt / Equity = 0.78 (Debt 108.0m / last Quarter total Stockholder Equity 139.0m)
Debt / EBITDA = -1.58 (Net Debt 37.1m / EBITDA -68.5m)
Debt / FCF = -0.96 (Debt 108.0m / FCF TTM -112.3m)
Total Stockholder Equity = 149.0m (last 4 quarters mean)
RoA = -26.46% (Net Income -93.3m, Total Assets 352.4m )
RoE = -62.62% (Net Income TTM -93.3m / Total Stockholder Equity 149.0m)
RoCE = -28.95% (Ebit -74.1m / (Equity 149.0m + L.T.Debt 107.0m))
RoIC = -26.39% (NOPAT -74.1m / Invested Capital 280.8m)
WACC = 9.23% (E(1.84b)/V(1.94b) * Re(9.64%)) + (D(108.0m)/V(1.94b) * Rd(2.80%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.94 | Cagr: 7.54%
Discount Rate = 9.64% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -112.3m)
Revenue Correlation: 91.45 | Revenue CAGR: 456.9%
Rev Growth-of-Growth: -70.01
EPS Correlation: 96.05 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 8.89
Additional Sources for ARQT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle